Cite
HARVARD Citation
Gligorov, J. et al. (n.d.). 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. Breast. pp. S21-S22. [Online].